chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19-2
Symptoms: Chills, Illness, Productive cough, Pyrexia
Clinical narrative: chills; fever; like if the patient had been sick a few days; Phlegm/coughing up discharge of sorts; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP), Program ID: The reporter is the patient. A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Moderna covid-19 vaccine (DOSE NUMBER UNKNOWN), for COVID-19 immunization. The following information was reported: CHILLS (non-serious), outcome "unknown"; PYREXIA (non-serious), outcome "unknown", described as "fever"; ILLNESS (non-serious), outcome "unknown", described as "like if the patient had been sick a few days "; PRODUCTIVE COUGH (non-serious), outcome "unknown", described as "Phlegm/coughing up discharge of sorts". Additional information: The patient wanted to share his/her side effects with after recent booster of the Pfizer bivalent vaccine. The patient had only been given all the prior Covid-19 vaccinations available to the patient at that time made by Moderna. This last and most recent booster was made by Pfizer and administered to the patient at his/her local (Facility name). The effects the patient had were more potent than that of Modernas prior ones. The patient had the chills, a fever and phlegm (reported as "flem") like if the patient had been sick a few days and coughing up discharge of sorts.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: She is calling for her son, who had the COVID vaccine but has COVID now and has a horrible cough; She is calling for her son, who had the COVID vaccine but has COVID now and has a horrible cough; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent (patient's mother).  A male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "She is calling for her son, who had the COVID vaccine but has COVID now and has a horrible cough". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: The patient on Paxlovid therapy, and would like to know if he can take a cough medication that wouldn't interact with the medication.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Hypersomnia, Lethargy, Sleep apnoea syndrome
Clinical narrative: very lethargic; sleep apnea; severe dizziness; slept many more hours than I normally do, in bed 12-14 hours after injection - normally 6-8 hours; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old female patient received BNT162b2 (BNT162B2), on 05Jan2022 at 13:00 as dose 3 (booster), single (Lot number: FD0809) at the age of 62 years intramuscular, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Osteoarthritis", start date: 01Jan2017 (unspecified if ongoing); "Spinal fusion" (unspecified if ongoing); "TKA Lt. Knee/TKA Rt. Knee" (unspecified if ongoing), notes: TKA Lt. Knee/TKA Rt. Knee. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose 1, Single time: 10:00 am, Anatomical site of injection: Right upper arm, Route of administration: Intramuscular, Batch\lot number: ER8733), administration date: 26Mar2021, for COVID-19 Immunization, reaction(s): "Severe dizziness", "Very lethargic"; BNT162b2 (Dose 1, Single time: 10:00 am, Anatomical site of injection: Right upper arm, Route of administration: Intramuscular, Batch\lot number: ER8733), administration date: 26Mar2021, for COVID-19 immunisation, reaction(s): "Sleep apnea", "Every time she bends over, if her head gets below her shoulders to pick something up she will black out", "Fever", "queasy", "everything in her body ached", "she had vertigo", "very tired"; BNT162b2 (Dose 2, Single, Anatomical site of injection: Right upper arm, Route of administration: Intramuscular, Batch\lot number: EW0158), administration date: 16Apr2021, for COVID-19 immunisation, reaction(s): "Very lethargic", "Severe dizziness", "Sleep apnea", "She fell asleep in her sunroom and got up around 3:00PM/ Went to bed early plus slept many more hours", "COPD", "She felt like she was on a boat/ she was not feeling", "had soreness in her arm", "has zero energy", "fever", "everything in her body ached ", "She felt like she was on a boat/ she was not feeling right". The following information was reported: LETHARGY (non-serious), outcome "unknown", described as "very lethargic"; SLEEP APNOEA SYNDROME (non-serious), outcome "unknown", described as "sleep apnea"; DIZZINESS (non-serious), outcome "unknown", described as "severe dizziness"; HYPERSOMNIA (non-serious), outcome "unknown", described as "slept many more hours than I normally do, in bed 12-14 hours after injection - normally 6-8 hours". Clinical course: After each injection, he experienced severe dizziness, very lethargic. Went to bed early and slept many more hours than he normally do. In bed 12-14 hours. After injection - normally 6-8 hours. He had been diagnosed with sleep apnea plus COPD since he had the injections. Sender's Comments: Linked Report(s): US-PFIZER INC-2021435489 same patient/drug, different dose/event; US-PFIZER INC-2021435657 same patient/drug, different dose/event;
Sex: U
Vaccine: TD
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: expired dose of Tenivac was administered to a patient with no reported adverse event; Initial information received on 15-Feb-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves an unknown age and unknown gender patient was administered expired dose of diphtheria and tetanus toxoids  (tenivac) was administered to a patient with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect diphtheria and tetanus toxoids via unknown route in unknown administration site for prophylactic vaccination (strength, formulation, dose, batch number and expiry date: unknown).  On an unknown date expired dose of tenivac was administered to a patient with no reported adverse event (expired product administered) (latency same day).  Action taken: not applicable  Outcome was Unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 28.0
Sex: F
Vaccine: DTAP
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: patient was administered the TDAP vaccine in the early weeks of her pregnancy with no adverse event; Initial information was received on 16-Feb-2023 regarding an unsolicited valid  non-serious case received from a pharmacist.  This case involves a 29 years old female patient who was exposed to vaccine DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE in context of patient was administered the tdap vaccine in the early weeks of her pregnancy with no adverse event.   Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known.   The reported patient was administered the TDAP vaccine in the early weeks of her pregnancy with no adverse event occurred at unknown gestation period the gestation period at onset and gestation period at exposure data needs to be populated, if available  The date of last menstrual period was not reported. The estimated due date was not reported. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies.    On 19-Aug-2022, the patient received a  dose of suspect DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE produced by unknown manufacturer (dose, formulation, strength, and expiry date: unknown) via unknown route in unknown administration site for prophylactic vaccination (Immunisation).  On 19-AUG-2022 the patient developed a non-serious patient was administered the tdap vaccine in the early weeks of her pregnancy with no adverse event (exposure during pregnancy) (latency same day).  it was reported " Pharmacist mentioned that the patient may have been in the early weeks of gestation back in 19Aug2022 when she received a dose of the TDAP, and wonder would that be harmful to the patient or fetus? Patient has not received the vaccine yet. She states the patient's OBGYN sent in a prescription for a TDAP vaccine. Patient received a dose of TDAP back on 19Aug2022 and may or may not have been in the early weeks of her pregnancy".   Relevant prenatal testing after exposure included   Action taken with DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE (DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE) was not applicable.  At time of reporting, the outcome was Unknown for the event patient was administered the tdap vaccine in the early weeks of her pregnancy with no adverse event.  Additionally, at time of reporting, the outcome of the pregnancy is unknown.
Age: 13.0
Sex: F
Vaccine: MNQ
Symptoms: Medication error, No adverse event, Poor quality product administered, Product storage error
Clinical narrative: a temperature excursion due to a malfunction with the refrigerator. The excursion lasted for 69 days 1041 hours and the temperature of the refrigerator was 56.0-63.0 degrees Fahrenheit with no reported AE; t.The vaccine was given post excursion to patient post excursion with on reported AE; Initial information received on 21-Feb-2023 regarding an unsolicited valid non-serious case received from a nurse.  This case is linked to case 2023SA061081.  This case involves a 13-year-old female patient and reporter reported temperature excursion due to a malfunction with the refrigerator. the excursion lasted for 69 days 1041 hours and the temperature of the refrigerator was 56.0-63.0 degrees fahrenheit and meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] was given post excursion to patient with on reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included althaea officinalis root, cinnamomum camphora essential oil, citrus aurantium oil, eucalyptus globulus leaf essential oil, mentha x piperita essential oil (Gardisil).  On 08-Feb-2023, the patient received 0.5 ml (milliliter) (once) of suspect meningococcal A-C-Y-W135 (T CONJ) vaccine, solution for injection (lot: U7048AA, expiry date: 28-Feb-2024) (strength: unknown) via intramuscular route in the right arm for immunization.  On an unknown date, reporter reported temperature excursion due to a malfunction with the refrigerator. the excursion lasted for 69 days 1041 hours and the temperature of the refrigerator was 56.0-63.0 degrees fahrenheit with no reported adverse event (product storage error) (unknown latency) and on 08-Feb-2023, vaccine was given post excursion to patient with on reported adverse event (poor quality product administered) following the administration of meningococcal A-C-Y-W135 (T CONJ) vaccine.  No lab data were reported.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for both events.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments:  See related case-01501093:
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Alopecia, Bone pain, Headache, Pain, Pain in extremity
Clinical narrative: Crown Hair Loss, Healing process with cuts on arms sense Dec 16, 2022  Exstream body pains, Both Leg pains. Bone pain in legs and arms. Headacks. Please Note: On Line 22 Your not able to put in the dose number for some reason it wont alow you to?
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Skin laceration
Clinical narrative: Crown Hair Loss, Healing process with cuts on arms sense Dec 16, 2022  Exstream body pains, Both Leg pains. Bone pain in legs and arms. Headacks. Please Note: On Line 22 Your not able to put in the dose number for some reason it wont alow you to?
Age: 0.17
Sex: M
Vaccine: HEP, UNK
Symptoms: Autism spectrum disorder, Growth retardation
Clinical narrative: My child  has been diagnosed with autism for  which a decline in his growth was noticed post vaccination.
Sex: M
Vaccine: VARZOS
Symptoms: Inappropriate schedule of product administration
Clinical narrative: 1st dose 2018, 2nd 4 months ago; This case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2018).   In October 2022, the patient received the 2nd dose of Shingrix. In October 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK Receipt Date: 15-FEB-2023 Reporter's Comments:  The patient self-reported this case. The patient received first dose of Shingrix in 2018 and second dose four months ago. The reporter did not consent to follow-up Additional Supportive Information: The patient received 2nd dose four months prior to reporting after receiving 1st dose, which led to lengthening of the recommended interval between vaccine doses. As per reported information patient received 2nd dose four months prior to reporting hence conservatively October 2022 was captured as vaccination date and event onset date.
Age: 2.0
Sex: F
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: Patient received 2nd dose expired; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 2-year-old female patient who received HAV (Havrix pediatric) for prophylaxis.   On 14th February 2023, the patient received the 2nd dose of Havrix pediatric. On 14th February 2023, unknown after receiving Havrix pediatric, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   Additional Information: GSK Receipt Date: 15-FEB-2023 Reporter's Comment: The patient received Havrix pediatric dose after the expiration date. No information on lot number and expiration date of Havrix was available at the moment of the call. The reporter consented to follow up by email Additional Supportive Information: The patient received Havrix pediatric dose after the expiration date, which led to expired vaccine used.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: COVID-19 (Confirmed); This spontaneous case was reported by a non-health professional and describes the occurrence of COVID-19 (COVID-19 (Confirmed)) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     The patient's past medical history included Bursa disorder, Back disorder, Prostate cancer in 2010 and Gout. Concurrent medical conditions included Psoriatic arthritis since 1984, Spondylarthritis since 1984, Psoriasis since 1984 and Smoker (approximately 8 cigarettes per day). Concomitant products included TOFACITINIB CITRATE (XELJANZ XR) from 22-Nov-2021 to an unknown date, UPADACITINIB (RINVOQ), METHOTREXATE and PREDNISONE for an unknown indication.   In March 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2022, the patient experienced COVID-19 (COVID-19 (Confirmed)). At the time of the report, COVID-19 (COVID-19 (Confirmed)) outcome was unknown.            The patient's other concomitant medications included unspecified oral non-steroidal anti-inflammatory drugs (NSAIDs) (ongoing) and narcotics (unspecified to current).  In Jan-2022 Xeljanz XR was discontinued due to inadequate initial response.  No treatment details were reported.
Age: 1.0
Sex: F
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: Expired Havrix administered; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 1-year-old female patient who received HAV (Havrix) (batch number EP47E, expiry date 6th February 2023) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 16th February 2023, the patient received Havrix and Havrix Pre-Filled Syringe Device. On 16th February 2023, unknown after receiving Havrix and Havrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 16-FEB-2023 Reporter's Comment: The reporter called to inquire any information when could revaccinate.  The reporter reported they inadvertently administered an expired Havrix dose to a patient on 16th February 2023.  The reporter did not consent to follow-up. Additional Supportive Information: The patient inadvertently administered an expired Havrix dose, which led to Expired vaccine used.
Sex: F
Vaccine: VARZOS
Symptoms: Fatigue, Headache, Injection site pain, Malaise
Clinical narrative: Pain in area where she received her shot; Not feeling well; Headache; Tiredness; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 15th February 2023, the patient received the 1st dose of Shingrix. In February 2023, unknown after receiving Shingrix, the patient experienced injection site pain, feeling unwell, headache and tiredness. On an unknown date, the outcome of the injection site pain, feeling unwell, headache and tiredness were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, feeling unwell, headache and tiredness to be related to Shingrix.     Additional Information: GSK Receipt Date: 16-FEB-2023 Reporter's comments: The patient self-reported this case.  The patient received her first dose of Shingrix on the left arm, one day before reporting and was not feeling well, had pain in the area where she received her shot, had a headache and was experiencing tiredness. The reporter did not consent to follow-up.
Sex: U
Vaccine: YF
Symptoms: Medication error, No adverse event, Product preparation error
Clinical narrative: yellow fever vaccine was mixed with a sterile diluent instead of the diluent that came with the vaccine with no reported adverse event; Initial information received on 27-Jan-2023 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves an unknown age and unknown gender patient to whom who given yellow fever vaccine - [YF-VAX] that was mixed with a sterile diluent instead of the diluent that came with the vaccine with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included typhoid vaccine (TYPHIM) for Immunisation.  On 27-Jan-2023, the patient received 0.5 ml once (1X) (total) dose of suspect yellow fever vaccine, solution for injection (strength; not reported; lot UJ563AA; ,Expiration Date :23-May-2023) via subcutaneous route in the left arm for Immunization was mixed with a sterile diluent instead of the diluent that came with the vaccine with no reported adverse event (product preparation error) (latency; same day).  Action taken: not applicable.  Outcome : Unknown.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 64.0
Sex: M
Vaccine: VARZOS
Symptoms: Headache, Injection site pain, Nausea, Neck pain, Pyrexia
Clinical narrative: injection site pain and tenderness fever headache neck ache nausa
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 88.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 91.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 19.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 94.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 96.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: It was discovered on 12/20/2022 that the Moderna vaccine that was administered was expired. Contacted Moderna and was advised that the vaccine was still viable at this time, therefore the vaccine was considered a valid dose, and patient does not need to be re-vaccinated.
Age: 78.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: covid positive pt, admitted, fully vaccinated